Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 4 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Introduction | 10 | 1 |
| Gene Therapy Market Technology Overview | 11 | 8 |
| Introduction | 11 | 1 |
| Gene | 11 | 1 |
| Genome | 11 | 1 |
| DNA | 11 | 1 |
| Nuclear DNA | 11 | 1 |
| Organelle DNA | 11 | 1 |
| Genetic Disorders | 11 | 1 |
| Gene Therapy | 12 | 1 |
| Types of Gene Therapies | 12 | 1 |
| Germ Line Gene Therapy | 12 | 1 |
| Somatic Gene Therapy | 13 | 1 |
| Need for Gene Therapy | 13 | 1 |
| Vectors Used in Gene Therapy | 13 | 1 |
| Viral Vectors | 13 | 1 |
| Adenoviral Vectors | 14 | 1 |
| Adeno-Associated Viral Vectors | 14 | 1 |
| Herpes Simplex Viral Vectors | 14 | 1 |
| Retroviral Vectors | 15 | 1 |
| Lentiviral Vectors | 15 | 1 |
| Vaccinia Viral Vectors | 16 | 1 |
| Complications in Using Viral Vectors for Gene Therapy | 16 | 1 |
| Non-Viral Vectors | 16 | 1 |
| Naked DNA Delivery by a Physical Method | 16 | 1 |
| Gene Delivery Using a Chemical Carrier | 17 | 1 |
| Role of Gene Therapy in the Pharmaceutical Industry | 18 | 1 |
| Upstream Action of Gene Therapies Makes Them More Effective Than the Existing Biologic Therapies | 18 | 1 |
| Upstream Mechanism of Action | 18 | 1 |
| Potential to Act through Natural Pathway | 18 | 1 |
| Potential to Target any Gene | 18 | 1 |
| Gene Therapy Market Clinical Development Trends | 19 | 5 |
| Gene Therapy Clinical Development by Year | 19 | 2 |
| Gene Therapy Clinical Development by Vectors Used | 21 | 1 |
| Gene Therapy Clinical Development by Geography | 22 | 1 |
| Gene Therapy Clinical Development by Therapy Area | 23 | 1 |
| Gene Therapy Market Market Environment Characterization | 24 | 10 |
| Market Drivers | 24 | 1 |
| Failure of Conventional Therapies to Treat Cancers and Other Indications has Created High Unmet Needs | 25 | 1 |
| Entry of Gene Therapies in Developed Nations Will Poise the Market Growth | 25 | 1 |
| Rising Incidence and Prevalence of Chronic and Life Threatening Diseases | 26 | 1 |
| Possible Treatment for Monogenic Conditions Can Give Access to Previously Undeveloped Markets | 26 | 1 |
| Market Restraints | 26 | 1 |
| Stringent Regulatory Laws Delay Gene Therapy Development | 26 | 1 |
| Safety Concerns | 26 | 1 |
| Short-Lived Nature of Gene Therapy | 26 | 1 |
| Immune Response | 26 | 1 |
| Problems with Viral Vectors | 27 | 1 |
| Multigenic Disorders | 27 | 1 |
| Chance of Inducing Cancer | 27 | 1 |
| Potential Germ Line Modification | 27 | 1 |
| Technical Limitations in Present Technology | 27 | 1 |
| Market Analysis | 28 | 1 |
| Strengths | 28 | 1 |
| Gene Therapies Hold a Competitive Edge over Conventional Therapies Due to Their Gene Modification Ability | 28 | 1 |
| Weakness | 28 | 1 |
| Although Gene Therapies Have the Potential to Cure Diseases, Certain Drawbacks Such as Instability and Side Effects are Preventing Them from Displaying Desired Efficacy Levels | 28 | 1 |
| Opportunities | 29 | 1 |
| Abundant Opportunities in Terms of Unmet Needs Exist for Gene Therapies in Chronic Disease Conditions Associated with Genetic Mutations and Protein Overexpression | 29 | 1 |
| Threats | 29 | 1 |
| Similar to Gene Therapies, Other Treatments such as Stem Cell Therapies are also in Research and Development, and These Therapies Can Pose a Threat to the Gene Therapeutics Market Potential | 29 | 1 |
| Current Marketed Products | 29 | 1 |
| Gendicine | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| Clinical Trial Details | 30 | 1 |
| Safety | 31 | 1 |
| Market | 31 | 1 |
| Oncorine | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| Clinical Trial Details | 31 | 1 |
| Safety | 32 | 1 |
| Rexin-G | 32 | 1 |
| Mechanism of Action | 32 | 1 |
| Clinical Trial Details | 32 | 2 |
| Gene Therapy Market Pipeline Analysis | 34 | 24 |
| Research and Development Analysis | 34 | 1 |
| R&D Pipeline by Phase | 34 | 1 |
| Phase III Molecules | 35 | 1 |
| Phase II Molecules | 36 | 1 |
| Phase I Molecules | 37 | 1 |
| IND Filed Molecules | 38 | 1 |
| Preclinical Molecules | 38 | 2 |
| Discovery Molecules | 40 | 1 |
| R&D Pipeline by Therapy Area | 41 | 1 |
| Oncology Diseases | 42 | 3 |
| Central Nervous System Disorders | 45 | 2 |
| Hematological Disorders | 47 | 2 |
| Ophthalmological Disorders | 49 | 2 |
| Promising Molecules in the Pipeline | 51 | 1 |
| Collategene | 51 | 1 |
| Overview | 51 | 1 |
| Mechanism of Action | 51 | 1 |
| Clinical Trial Details | 51 | 1 |
| Allovectin-7 | 52 | 1 |
| Overview | 52 | 1 |
| Mechanism of Action | 52 | 1 |
| Clinical Trial Details | 53 | 1 |
| Generx | 53 | 1 |
| Overview | 53 | 1 |
| Mechanism of Action | 53 | 1 |
| Clinical Trial Details | 53 | 1 |
| Failed Late Stage Products | 54 | 1 |
| Glybera | 54 | 1 |
| Overview | 54 | 1 |
| Mechanism of Action | 54 | 1 |
| Clinical Trial Details | 54 | 1 |
| Cerepro | 55 | 1 |
| Overview | 55 | 1 |
| Mechanism of Action | 55 | 1 |
| Clinical Trial Details | 55 | 1 |
| NV1FGF | 56 | 1 |
| Overview | 56 | 1 |
| Mechanism of Action | 56 | 1 |
| Clinical Trial Details | 56 | 1 |
| TNFerade | 57 | 1 |
| Overview | 57 | 1 |
| Mechanism of Action | 57 | 1 |
| Clinical Trial Details | 57 | 1 |
| Gene Therapy Market Regulatory Landscape | 58 | 2 |
| Gene Therapy and the Regulatory Environment | 58 | 1 |
| The US | 58 | 1 |
| FDA Center for Biologics Evaluation and Research (CBER) | 58 | 1 |
| NIH Recombinant DNA Advisory Committee (RAC) | 58 | 1 |
| Europe | 58 | 1 |
| European Medicines Agency (EMEA) | 58 | 1 |
| Japan | 59 | 1 |
| Ministry of Health and Welfare (MHW) | 59 | 1 |
| Gene Therapy Market Competetive Landscape | 60 | 11 |
| Profiles of Major Companies in Gene Therapy R&D | 60 | 2 |
| ReGenX Biosciences | 62 | 1 |
| Overview | 62 | 1 |
| SWOT Analysis | 62 | 1 |
| Oxford BioMedica plc | 63 | 1 |
| Overview | 63 | 1 |
| SWOT Analysis | 63 | 1 |
| EGEN | 64 | 1 |
| Overview | 64 | 1 |
| SWOT Analysis | 64 | 1 |
| Sangamo BioSciences | 65 | 1 |
| Overview | 65 | 1 |
| SWOT Analysis | 65 | 1 |
| BioSante Pharmaceuticals | 66 | 1 |
| Overview | 66 | 1 |
| SWOT Analysis | 66 | 1 |
| Amsterdam Molecular Therapeutics (AMT) | 67 | 1 |
| Overview | 67 | 1 |
| SWOT Analysis | 67 | 1 |
| Recent Deals in the Gene Therapy Market | 68 | 1 |
| MolMed Enters into an Agreement with Fondazione Telethon | 68 | 1 |
| GlaxoSmithKline Enters into Co-Development Agreement with McGill University | 68 | 1 |
| Amsterdam Molecular Therapeutics Enters into an Agreement with Institut Pasteur and the Consortium | 68 | 1 |
| Oxford BioMedica Enters into Research Agreement with Mayo Clinic | 69 | 1 |
| RetroSense Therapeutics Enters into Licensing Agreement with Wayne State University | 69 | 1 |
| Amsterdam Molecular Expands Licensing Agreement with National Institute of Health | 69 | 1 |
| GlaxoSmithKline Enters into Licensing Agreement with Fondazione Telethon | 69 | 1 |
| GlaxoSmithKline Enters into Strategic Alliance with Fondazione Telethon and Fondazione San Raffaele | 70 | 1 |
| Bluebird bio Enters into Licensing Agreement with INSERM | 70 | 1 |
| Gene Therapy Market Appendix | 71 | 6 |
| Abbreviations | 71 | 1 |
| Market Definitions | 72 | 1 |
| Research Methodology | 73 | 4 |
| Coverage | 73 | 1 |
| Secondary Research | 73 | 1 |
| Primary Research | 73 | 1 |
| Expert Panel Validation | 74 | 1 |
| Section-wise Research Methodology | 74 | 1 |
| Technology Overview | 74 | 1 |
| Clinical Development Landscape | 74 | 1 |
| Market Environment Characterization | 75 | 1 |
| Pipeline Analysis | 75 | 1 |
| Regulatory Landscape | 75 | 1 |
| Competitive Landscape | 76 | 1 |
| Sources | 76 | 1 |
| Contact Us | 76 | 1 |
| Disclaimer | 76 | 1 |